Standard Biotools Inc.: Form 10-Q for the period ended Jun 30, 2017
Filed with the SEC on Aug 8, 2017 and accepted by EDGAR at Aug 8, 2017, 17:11 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2017-06-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Cost of revenue | 3 months2017-04-01 to 2017-06-30 | $10.8m | us-gaap:CostOfGoodsSold |
| Cost of revenue | 6 months2017-01-01 to 2017-06-30 | $21.6m | us-gaap:CostOfGoodsSold |
| Research and development | 3 months2017-04-01 to 2017-06-30 | $7.5m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months2017-01-01 to 2017-06-30 | $16.0m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months2017-04-01 to 2017-06-30 | $21.0m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 6 months2017-01-01 to 2017-06-30 | $43.6m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2017-04-01 to 2017-06-30 | −$16.5m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2017-01-01 to 2017-06-30 | −$34.0m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2017-04-01 to 2017-06-30 | $1.5m | us-gaap:InterestExpense |
| Interest expense | 6 months2017-01-01 to 2017-06-30 | $2.9m | us-gaap:InterestExpense |
| Income tax | 3 months2017-04-01 to 2017-06-30 | −$827.0k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months2017-01-01 to 2017-06-30 | −$2.6m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2017-04-01 to 2017-06-30 | −$16.9m | us-gaap:NetIncomeLoss |
| Net income | 6 months2017-01-01 to 2017-06-30 | −$34.1m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2017-04-01 to 2017-06-30 | −$0.58 | us-gaap:EarningsPerShareBasicAndDiluted |
| Diluted EPS | 6 months2017-01-01 to 2017-06-30 | −$1.17 | us-gaap:EarningsPerShareBasicAndDiluted |
| Operating cash flow | 6 months2017-01-01 to 2017-06-30 | −$16.8m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months2017-01-01 to 2017-06-30 | $834.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2017-06-30 | $39.6m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2017-06-30 | $79.1m | us-gaap:AssetsCurrent |
| Total assets | At period end2017-06-30 | $278.7m | us-gaap:Assets |
| Current liabilities | At period end2017-06-30 | $34.3m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2017-06-30 | $254.8m | us-gaap:Liabilities |
| Shareholders' equity | At period end2017-06-30 | $23.9m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001162194-17-000091. Last ingested by Listed: Nov 5, 2026, 21:16 ET. Listed shows no prices and gives no investment advice.